ASH Preview of the 2017 Meeting on Hematologic Malignancies: Focus on Myeloproliferative Neoplams/CML



Thinking of attending the 2017 ASH Meeting on Hematologic Malignancies? Join us for the first in a series of special webinar previews of the 2017 meeting. Listen to speakers from the meeting as they preview their presentations, then stay for a special Q&A session to talk directly to meeting organizers and find out why you should join us in Chicago in September 2017!

The ASH Meeting on Hematologic Malignancies includes five core malignant hematology themes: leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, and myeloma. This Focus on Myeloproliferative Neoplasms (MPN) webinar will feature a discussion with three clinicians in the area of MPNs regarding how clinical practice has evolved in recent years, as well as discussion of important conclusions from the previous year’s meeting. The doctors will also discuss what to expect in the coming year, with emphasis on how “How I Treat” is a different approach than the classic format of educational and or scientific sessions.

The webinar will include a special Q&A session with meeting organizers for participants to chat about anything related to the meeting or registration.

The next ASH Meeting on Hematologic Malignancies will be held in Chicago, IL, September 8-9, 2017. The program’s “How I Treat” presentations showcase speakers’ evidence-based treatment approaches, identify cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and address what to do in cases where there is no data. This meeting is a unique opportunity to join colleagues and top experts in treatment of hematologic malignancies in an intimate, smaller-meeting setting and discuss the latest drug developments and most relevant research findings advancing patient care today.

Visit for information related to next year’s meeting!


  • Ruben Mesa, MD, Mayo Clinic Cancer Center, Phoenix
  • Jason Gotlib, MD, Stanford Cancer Center
  • Jerry Radich, MD, Fred Hutchinson Cancer Research Center

back to top